Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
-- Provide an Update on the RSV F Vaccine Development Program
GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
- Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
- Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
- Update on the Prepare™ trial for Infants via Maternal Immunization
Conference call details are as follows:
Date: |
Monday, July 24, 2017 |
Time: |
4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: |
(877) 212-6076 (Domestic) or (707) 287-9331 (International) |
Passcode: |
54820069 |
Webcast: |
www.novavax.com, "Investors"/ "Events" |
Conference call and webcast replay:
Dates: |
Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017 |
Dial-in number: |
(855) 859-2056 (Domestic) or (404) 537-3406 (International) |
Passcode: |
54820069 |
Webcast: |
www.novavax.com, "Investors"/ "Events", until October 24, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
[email protected]
[email protected]
212-845-4271
SOURCE Novavax, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article